Adhera Therapeutics, Inc.
ATRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ATRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Market Cap
$722
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Sep 30, 2023.
Tracking 3 clinical trials · 1 FDA decision for Adhera Therapeutics, Inc..
Run Adhera Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Adhera Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 3.9%
- Days to cover
- 3.2
- Shares short
- 2,046
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATRX short interestGovernance
Frequently asked questions
Who is the CEO of Adhera Therapeutics, Inc.?
Chief Executive Officer is the chief executive officer of Adhera Therapeutics, Inc. (ATRX).
Where is Adhera Therapeutics, Inc. headquartered?
Adhera Therapeutics, Inc. (ATRX) is headquartered in Baton Rouge, LA, United States.
What therapeutic areas does Adhera Therapeutics, Inc. focus on?
Adhera Therapeutics, Inc. develops therapies across Neurology, Infectious Disease, Metabolic, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.